TOP TEN perturbations for 38856_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38856_at
Selected probe(set): 213974_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38856_at (213974_at) across 6674 perturbations tested by GENEVESTIGATOR:
lung adenocarcinoma study 3 (positive) / normal lung tissue
Relative Expression (log2-ratio):-4.975975Number of Samples:7 / 3
| Experimental | lung adenocarcinoma study 3 (positive) |
| Primary lung adenocarcinoma samples, with bone marrow positive for early disseminated tumor cells (DTCs). The presence of DTCs can predict the subsequent occurrence of overt metastasis and survival in lung cancer. | |
| Control | normal lung tissue |
| Normal lung tissue. |
stem cell differentiation study 47 (BMP-2; TGFb; 7d) / stem cell differentiation study 47 (0d)
Relative Expression (log2-ratio):4.5704927Number of Samples:3 / 6
| Experimental | stem cell differentiation study 47 (BMP-2; TGFb; 7d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and transforming growth factor beta (TGFb, 5 ng/ml). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). | |
| Control | stem cell differentiation study 47 (0d) |
| Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). |
lung adenocarcinoma study 3 (negative) / normal lung tissue
Relative Expression (log2-ratio):-4.5426855Number of Samples:9 / 3
| Experimental | lung adenocarcinoma study 3 (negative) |
| Primary lung adenocarcinoma samples, with bone marrow negative for early disseminated tumor cells (DTCs). The presence of DTCs can predict the subsequent occurrence of overt metastasis and survival in lung cancer. | |
| Control | normal lung tissue |
| Normal lung tissue. |
pancreatic cancer study 3 (ipmn) / normal pancreas tissue
Relative Expression (log2-ratio):-4.0671244Number of Samples:3 / 6
| Experimental | pancreatic cancer study 3 (ipmn) |
| Intraductal papillary mucinous neoplasm from patients with pancreatic cancer. | |
| Control | normal pancreas tissue |
| Normal human pancreatic tissue. |
lung adenocarcinoma study 6 (K-RAS mut) / adjacent lung tissue
Relative Expression (log2-ratio):-4.0606346Number of Samples:6 / 20
| Experimental | lung adenocarcinoma study 6 (K-RAS mut) |
| Primary tumor sample from patients with stage II adenocarcinoma carrying a K-RAS mutation. | |
| Control | adjacent lung tissue |
| Adjacent and histologically normal, non-tumorous lung tissue samples from patients with lung adenocarcinoma. |
pancreatic cancer study 3 (ipmc) / normal pancreas tissue
Relative Expression (log2-ratio):-3.996769Number of Samples:6 / 6
| Experimental | pancreatic cancer study 3 (ipmc) |
| Intraductal papillary mucinous carcinoma from patients with pancreatic cancer. | |
| Control | normal pancreas tissue |
| Normal human pancreatic tissue. |
myotonic dystrophy study 4 (deltoid muscle; DM-like) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-3.9942598Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (deltoid muscle; DM-like) |
| Deltoid muscle biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
stem cell differentiation study 47 (BMP-2; IBMX; 7d) / stem cell differentiation study 47 (BMP-2; TGFb; 7d)
Relative Expression (log2-ratio):-3.8747902Number of Samples:3 / 3
| Experimental | stem cell differentiation study 47 (BMP-2; IBMX; 7d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). | |
| Control | stem cell differentiation study 47 (BMP-2; TGFb; 7d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and transforming growth factor beta (TGFb, 5 ng/ml). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). |
Becker muscular dystrophy study 3 (biceps brachii) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-3.7913542Number of Samples:3 / 3
| Experimental | Becker muscular dystrophy study 3 (biceps brachii) |
| Biceps brachii biopsies obtained from patients with Becker muscular dystrophy (BMD). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (biceps brachii; DM-like) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-3.7673607Number of Samples:9 / 3
| Experimental | myotonic dystrophy study 4 (biceps brachii; DM-like) |
| Biceps brachii biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |